BioPorto A/S (THOXF)
| Previous close | 0.7500 |
| Open | 0.7500 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 0.7500 - 0.7500 |
| 52-week range | 0.6439 - 0.7500 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 251.01M |
| Beta (5Y monthly) | 1.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0300 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
BioPorto Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.S.
COPENHAGEN, Denmark and BOSTON, June 28, 2022 (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced its achievement of targeted subject enrollment for the third part of a 3-part clinical study to support a U.S. Food and Drug Administration (FDA) De Novo submission for use of The NGAL Test in identifying patients under the age of 22 at risk for Acute Kidney Injury (AKI). “We are very pleased to have reached the study’s planned enrollment of 600 patients by the end of Q2, as pre
- GlobeNewswire
Moderated Webcast with BioPorto’s Management
COPENHAGEN, Denmark and BOSTON, June 21, 2022 (GLOBE NEWSWIRE) -- BioPorto A/S (CPH:BIOPOR) (BioPorto) today provided details of a previously announced session with members of its management team. Tony Pare, CEO, and Neil Goldman, Executive VP & CFO, will participate in a webcast hosted by HC Andersen Capital (HCA) on Wednesday, June 29, 2022, at 2:00 p.m. CET (8:00 a.m. ET). HCA will moderate questions from the participating audience. To attend, please register at HCA’s website using the link:
- GlobeNewswire
BioPorto Appoints World Leading Expert and Pioneer on the Clinical Utility of the NGAL Biomarker, Dr. Prasad Devarajan, MD FAAP FASN, as New Senior Medical Director
June 20, 2022News release BioPorto Appoints World Leading Expert and Pioneer on the Clinical Utility of the NGAL Biomarker, Dr. Prasad Devarajan, MD FAAP FASN, as New Senior Medical Director COPENHAGEN, DENMARK and BOSTON, MA, USA, June 20, 2022, (GLOBE NEWSWIRE) -- BioPorto A/S (CPH:BIOPOR) (BioPorto) today announced the appointment of Dr. Prasad Devarajan, MD FAAP FASN, as Senior Medical Director effective July 1, 2022. Dr. Devarajan is considered a world leading Pediatric Nephrologist and phy
